Results 231 to 240 of about 58,972 (283)
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. [PDF]
Hart A +15 more
europepmc +1 more source
Demographic and Clinical Insights Into Pyoderma Gangrenosum: A Retrospective Cross-Sectional Study From a Tertiary Care Hospital. [PDF]
Mirzaei M +3 more
europepmc +1 more source
Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All
Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic +2 more
wiley +1 more source
Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series. [PDF]
Magnatta A +16 more
europepmc +1 more source
Prediction of infliximab and anti-drug antibody concentrations in patients with inflammatory bowel disease using machine learning models with real-world data from a prospective cohort study. [PDF]
Kim M +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dermatologic Therapy, 2004
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
openaire +3 more sources
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
openaire +3 more sources

